tri semaglutide Tirzepatide vs. Semaglutide: Understanding Your Weight Loss Medication Options New FDA-approved 'Wegovy HD' offers

The most common AEs across both studies were GI related (Table 3)

This includes variations between the type of GLP-1 agent, dose, duration of therapy or underlying patient phenotype such as body mass and metabolic rate, patients age, muscle activity, previous toxin treatments, and/or dosage

As of October 2025, 13 Medicaid state plans cover at least one GLP1 receptor agonist

Drug war erupts The fallout between Hims & Hers and Novo Nordisk centers on its sales of compounded versions of Wegovy, a drug people inject to decrease hunger so they eat less and lose weight

Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency